Edgestream Partners L.P. Makes New $3.95 Million Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Edgestream Partners L.P. purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 54,747 shares of the company's stock, valued at approximately $3,947,000. Edgestream Partners L.P. owned 0.11% of Prestige Consumer Healthcare as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PBH. Boston Trust Walden Corp acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth $41,785,000. Ariel Investments LLC lifted its stake in shares of Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock valued at $195,204,000 after purchasing an additional 274,212 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Prestige Consumer Healthcare by 26.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company's stock worth $90,891,000 after purchasing an additional 272,773 shares during the period. Victory Capital Management Inc. increased its position in Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company's stock worth $142,827,000 after purchasing an additional 171,357 shares in the last quarter. Finally, F M Investments LLC purchased a new position in Prestige Consumer Healthcare in the second quarter valued at approximately $11,162,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

PBH has been the subject of several research reports. Jefferies Financial Group reiterated a "hold" rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a "buy" rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Prestige Consumer Healthcare Stock Up 0.7 %

NYSE PBH traded up $0.60 on Friday, reaching $84.77. The company had a trading volume of 164,911 shares, compared to its average volume of 302,709. The firm has a market capitalization of $4.19 billion, a PE ratio of 20.63, a P/E/G ratio of 2.38 and a beta of 0.47. The firm has a 50-day moving average of $75.41 and a 200-day moving average of $71.19. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the firm earned $1.07 earnings per share. The business's quarterly revenue was down .9% compared to the same quarter last year. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Insider Activity

In other Prestige Consumer Healthcare news, insider William P'pool sold 8,987 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares of the company's stock, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company's stock, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.